Delighted to present these data today at #ESCCongress looking at the potential benefits of the early initiation of disease-modifying therapy in community-based patients with suspected HF Simultaneous publication at @ESC_Journals EHJ https://t.co/1mjvXC3wIZ

Elevated IL-6 & hs-CRP levels = higher risk of worsening HF or #cvDeath in #HFrEF patients, based on DAPA-HF study. ✅ However, #dapagliflozin reduced outcomes regardless of baseline inflammation 📎 https://t.co/AAQtJovnUi #JACCHF #HeartFailure @scottdsolomon

📣Can wearable accelerometers predict HF outcomes? Original research with a subgroup of DETERMINE trial patients showed: ⬇️Physical activity assessed by accelerometer🏃🏾‍♂️ --> ⬇️KCCQ, ⬇️ 6MWD, ⬆️ NT-proBNP #Wearables #HFoutcomes 🔗 https://t.co/Awbd6eIrwa

#PREVENTHF launching Mar '25 New large first-of-its-kind #CKM trial focused on *prevention* of HF n=11,300 pts w T2D, ASCVD, HTN (but w/o HF) Randomization: ASi (baxdrostat) + SGLT2i (dapagliflozin) vs SGLT2i alone PEP: new diagnosis of HF or CV death https://t.co/GBkU7ER6da

EMPRESS-MI now published. No effect of empagliflozin on ventricular remodelling in patients with LVEF ≤45% following acute MI. However...very few patients had progressive adverse remodelling. The challenge is identifying patients at risk of adverse remodelling in the modern era.

Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in HFmrEF/HFpEF: a Prespecified Analysis of The FINEARTS-HF Trial Now online @CircAHA after presentation at #HFSA2024 Consistent benefit of finerenone regardless of LVEF https://t.co/Hp8RUBF7PQ

An age-old hemodynamics debate: pressure vs volume. Pressure-guided RPM are available, but what about volume? 🚨FUTURE-HF2 trial: Out Now in @JCardFail! Safety & feasibility of the FIRE1 implantable IVC sensor from #HFSA2024 🔗 https://t.co/lU3nZjapJ8

Delighted to present these data today from the DETERMINE trials at the #ESCCongress The first evidence of a beneficial effect of a HF therapy on accelerometer-based measures of physical activity. A promising new outcome measure for HF trials.

Simultaneous Publication w/ #ESCCongress 2024 from @UoGHeartFailure & @Kieranfdocherty et al: Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients with Heart Failure: An Analysis of the DETERMINE Trials https://t.co/aB1105OKCs #AHAJournals

As #ESCCongress kicks off, I am proud to share this review article on Digital Tools in Heart Failure, where we tried to cover all aspects of this promising field Open access @LancetDigitalH 😊 https://t.co/43rw3VLTbU @DrJasper1 @Kieranfdocherty @CMichaelGibson @lamcardio

New review in #JACCHF by @Kieranfdocherty on the treatment and prevention of HF following AMI. * Review of current evidence and guideline recommendations * Discussion of ongoing research * Proposal to identify highest risk pts to guide tx 🔥Don't miss!! https://t.co/qUUkVL5axj

Great to see the design paper of our mechanistic remodelling trial of SGLT2i following acute MI published - final study visits in the next few weeks and hopefully results will be ready to present later this year!

EMPRESS-MI will assess the effect of the SGLT2 inhibitor empagliflozin on cardiac remodelling in patients with LVSD after an acute MI. https://t.co/vBcTTchMoQ @CarberryJaclyn @markcpetrie20 @ColinBerryMD @Kieranfdocherty @UoGHeartFailure @UofGSCMH @BHFCoREGlasgow #HF #MI #SGLT2i

Honored, humbled and very excited to be selected as candidate for position of president-elect for the #HFA board elections! To all members, please don’t forget to vote for these fantastic people! https://t.co/LJrkdSZgSX Here are my top six priorities....together we can make it

To become the future of the clinical trials, apply here : https://t.co/ArvitDllIh #CardioTwitter #Diversity #clinicalresearch

Sacubitril/valsartan and Alzheimer's disease biomarkers. Great collaboration with @wagnersbrum demonstrating an important drug-test interaction with a commonly used AD blood test (Aβ42/Aβ40). Also reassuring results in other biomarkers of neurodegeneration https://t.co/UZa40JzL8t

Fantastic few days at @CVCTForum. Great talks on recent and upcoming trials with some thought provoking discussions and an opportunity to catch up with friends and colleagues. Thanks to @FaiezZANNAD for the opportunity and support through the Young Clinical Trialist Fellowship

Enroute to Philadelphia for #AHA23 Will be presenting some new data from DAPA-HF on Monday at 10:30AM - Interleukin-6 in Patients With HFrEF and the Effect of Dapagliflozin (Poster Board 2229)

Subcutaneous furosemide for patients with heart failure. Promising results of 2 phase I trials. Published this week and featured in today's episode of ESC TV Today. https://t.co/OeMrSzdhg1 #furosemide #SQfurosemide https://t.co/32MnDG5IyI